ArticleJournal of bone and mineral metabolism2026
Acute-phase reaction and fracture outcomes from zoledronic acid: a systematic review and meta-analysis.
Article in Journal of bone and mineral metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionZoledronic acid (ZOL), an intravenous bisphosphonate used to treat osteoporosis, is frequently associated with the development of an acute-phase reaction (APR). Although some studies have reported that the APR may correlate with fracture outcomes, the evidence remains inconsistent. This systematic review and meta-analysis aimed to investigate the association between the occurrence of an APR and fracture outcomes following ZOL therapy. MATERIALS AND
methodsWe searched MEDLINE, EMBASE, CENTRAL, International Clinical Trials Registry Platform, and ClinicalTrials.gov through April 2025 for observational studies and secondary analyses of randomized controlled trials in adults with osteoporosis. The primary outcome was the incidence of osteoporotic fractures. Secondary outcomes were mortality and changes in bone mineral density (BMD) and bone turnover markers (BTMs). The meta-analyses were performed using random-effects models and the certainty of evidence was assessed using the GRADE approach.
resultsSeven studies were included in the final analysis. No significant association was observed between APR and fracture risk (all fractures: odds ratio (OR) 0.79, 95% confidence interval (CI) 0.19-3.26; vertebral fractures: OR 0.76, 95%CI 0.17-3.32). Similarly, no significant association was found between developing an APR and all-cause mortality, or changes in BMD, or BTMs. The certainty of the evidence ranged from very low to moderate.
conclusionCurrent evidence is insufficient to establish a clear association between ZOL-induced APR and fracture risk, mortality, or BMD outcomes among patients with osteoporosis. To accurately capture potential associations, future large-scale prospective studies should enroll high-risk patients, including bisphosphonate-naïve individuals, and evaluate baseline BTMs and short-term mortality.
Indexed as
Identifiers
42836967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.